



21 April 2009

Xifaxan Wins a Prestigious Medical Innovation Award

Norgine, the leading European specialty pharmaceutical company, has been awarded the Creutzfeldt Award in Germany.

The annual H.G. Creutzfeldt Award celebrates innovative medicines, people or companies that show outstanding efforts to improve patient's welfare.

The prize was awarded to XIFAXAN® a revolutionary, highly selective broad spectrum antibiotic which is used to treat traveller's diarrhoea. XIFAXAN acts only in the gut and is minimally absorbed, therefore less likely to cause systemic antibiotic resistance or interfere with gut flora – both of which are of great concern to the medical profession.

Commenting on the award, Hansjoerg Meyer, the XIFAXAN Brand Manager said "We are very proud to accept this award. Since the Marketing Approval by the BfArM, Norgine has been working closely with Alfa Wassermann, the originator of the active ingredient: rifaximin- α , to further enhance the therapeutic advantages of this novel and effective antibiotic to the German market and we are very pleased it has got the recognition it deserves"

ENDS